On being the statistician on a data and safety monitoring board

Statistics in Medicine

Volumn 18, Issue 24, 1999, Pages 3425-3434

  Whitehead, John ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DATA ANALYSIS; MEDICAL ETHICS; PATIENT RIGHT; STATISTICAL ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DRUG MONITORING; HUMANS;

EID: 0033619965     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19991230)18:24<3425::AID-SIM369>3.0.CO;2-D     Document Type: Conference Paper

References (19)

1. Armitage, P. 'Interim analysis in clinical trials', Statistics in Medicine, 10, 925-937 (1991).
2. Ellenberg, S., Geller, N., Simon, R. and Yusuf, S. (eds). 'Practical issues in data monitoring of clinical trials', Statistics in Medicine, 12, 414-616 (1993).
3. DeMets, D. L. 'Data and safety monitoring boards', in Armitage, P. and Colton, T. (eds), The Encyclopedia of Biostatistics, Wiley, Chichester, 1998.
4. Armstrong, P. W. and Furberg, C. D. 'Clinical trial data and safety monitoring boards: The search for a constitution', Circulation, 91, 901-904 (1995).
5. International Conference on Harmonisation. 'Statistical principles for clinical trials (E9)', London, 1998.
6. Medical Research Council. Guidelines for Good Clinical Practice, Medical Research Council, London, 1998.
7. Facey, K. M. and Lewis, J. A. 'The management of interim analyses in drug development', Statistics in Medicine, 17, 1801-1809 (1998).
8. Meinert, C. L. 'Clinical trials and treatment effects monitoring' (with discussion), Controlled Clinical Trials, 19, 515-543 (1998).
9. Whitehead, J. The Design and Analysis of Sequential Clinical Trials, revised 2nd edn, Wiley, Chichester, 1997.
10. Jennison, C. and Turnbull, B. W. 'Group sequential tests for bivariate response: interim analysis of clinical trials with both efficacy and safety endpoints', Biometrics, 49, 741-752 (1993).
11. Cook, R. J. and Farewell, V. T. 'Guidelines for monitoring efficacy and toxicity responses in clinical trials', Biometrics, 50, 1146-1152 (1994).
12. Todd, S. 'Sequential designs for monitoring two endpoints in a clinical trial', Drug Information Journal, 33, 417-426 (1999).
13. Jennison, C. and Turnbull, B. W. 'Statistical approaches to interim monitoring of medical trials: A review and commentary', Statistical Science, 5, 229-317 (1990).
14. Spiegelhalter, D. J., Freedman, L. S. and Parmar, M. K. B. 'Bayesian approaches to randomised trials' Journal of the Royal Statistical Society Series A, 157, 357-416 (1994).
15. Scharfstein, D. O., Tsiatis, A. A. and Robins, J. M. 'Semiparametric efficiency and its implication on the design and analysis of group-sequential studies', Journal of American Statistical Association, 92, 1342-1350 (1997).
16. Whitehead, A. 'A prospectively planned cumulative meta-analysis applied to a series of concurrent clinical trials', Statistics in Medicine, 16, 2901-2913 (1997).
17. Meinert, C. L. 'Masked monitoring in clinical trials - blind stupidity?', New England Journal of Medicine, 338, 1381-1382 (1998).
18. Fairbanks, K. and Madsen, R. 'P values for tests using a repeated significance test design', Biometrika, 69, 69-74 (1982).
19. Whitehead, J. 'Overrunning and underrunning in sequential clinical trials', Controlled Clinical Trials, 13, 106-121 (1992).